Alexander M. M. Eggermont, MD, PhD | Authors

Articles

Results of Pembrolizumab in High-Risk Stage III Melanoma

April 17, 2018

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the phase III results from the EORTC 1325-MG/KEYNOTE-054 trial presented at the 2018 AACR Annual Meeting.